51.70

1.83% 0.93

Pre-market: 51.51 -0.19 -0.37%

Anaptysbio Inc (ANAB)

Overview News Price History Option Chain Financials Discussions Forecast

Anaptysbio Inc stock is traded at $51.70, with a volume of 417.82K. It is up +1.83% in the last 24 hours and down -11.53% over the past month. AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Previous Close:

$50.77

Open:

$50.59

24h Volume:

417.82K

Relative Volume:

0.71

Market Cap:

$1.55B

Revenue:

$232.39M

Net Income/Loss:

$-26.79M

P/E Ratio:

-47.85

EPS:

-1.0804

Net Cash Flow:

$4.41M

1W Performance:

-6.10%

1M Performance:

-11.53%

6M Performance:

-17.96%

1Y Performance:

+133.51%

1-Day Range:

$50.35

$52.16

1-Week Range:

$49.45

$56.04

52-Week Range:

$20.79

$73.30

Anaptysbio Inc Stock (ANAB) Company Profile

Name

Anaptysbio Inc

Sector

Healthcare (1068)

Industry

Biotechnology (595)

Phone

858-362-6295

Address

10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA

Employee

104

Twitter

@anaptysbio

Next Earnings Date

2026-11-03

Latest SEC Filings

ANAB's Discussions on Twitter

Compare ANAB vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANAB Anaptysbio Inc	51.70	1.55B	232.39M	-26.79M	4.41M	-1.0804
VRTX Vertex Pharmaceuticals Inc	522.38	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.02	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.82	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	962.22	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	199.86	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-26	Resumed	UBS	Buy
Oct-13-25	Initiated	Barclays	Overweight
Jun-04-25	Upgrade	H.C. Wainwright	Neutral → Buy
Feb-04-25	Initiated	Wolfe Research	Outperform
Dec-11-24	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-02-24	Downgrade	BTIG Research	Buy → Neutral
Jul-22-24	Initiated	H.C. Wainwright	Buy
Jul-19-24	Upgrade	JP Morgan	Neutral → Overweight
Apr-16-24	Initiated	Leerink Partners	Outperform
Apr-11-24	Initiated	Wells Fargo	Overweight
Mar-12-24	Upgrade	Wedbush	Neutral → Outperform
Feb-26-24	Initiated	BTIG Research	Buy
Feb-21-24	Initiated	Stifel	Buy
Feb-16-24	Initiated	Piper Sandler	Overweight
May-22-23	Upgrade	JP Morgan	Underweight → Neutral
May-18-23	Initiated	TD Cowen	Outperform
Jan-06-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-01-22	Upgrade	Guggenheim	Neutral → Buy
Sep-19-22	Resumed	H.C. Wainwright	Buy
Sep-13-22	Downgrade	Truist	Buy → Hold
Sep-01-22	Initiated	Raymond James	Outperform
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Jun-22-21	Initiated	H.C. Wainwright	Buy
May-21-21	Initiated	UBS	Neutral
Mar-16-21	Upgrade	Truist	Hold → Buy
Mar-09-21	Downgrade	Wedbush	Outperform → Neutral
Mar-08-21	Downgrade	JP Morgan	Overweight → Underweight
Feb-11-21	Upgrade	JP Morgan	Underweight → Overweight
Oct-27-20	Upgrade	Wedbush	Neutral → Outperform
Oct-14-20	Upgrade	Guggenheim	Neutral → Buy
Nov-08-19	Downgrade	JP Morgan	Overweight → Underweight
Nov-08-19	Downgrade	Jefferies	Buy → Hold
Nov-08-19	Downgrade	SunTrust	Buy → Hold
Nov-08-19	Downgrade	Wedbush	Outperform → Neutral
Jun-21-19	Downgrade	Credit Suisse	Outperform → Neutral
Jun-21-19	Downgrade	Stifel	Buy → Hold
Dec-20-18	Initiated	H.C. Wainwright	Buy
Nov-21-18	Initiated	JP Morgan	Overweight
Jul-19-18	Initiated	Credit Suisse	Outperform
Apr-04-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Mar-27-18	Reiterated	Stifel	Buy
Mar-06-18	Reiterated	Stifel	Buy
Feb-15-18	Reiterated	SunTrust	Buy
Jan-23-18	Reiterated	Credit Suisse	Outperform
Nov-15-17	Initiated	SunTrust	Buy
Nov-09-17	Initiated	Jefferies	Buy
Oct-11-17	Reiterated	RBC Capital Mkts	Outperform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform

View All

Anaptysbio Inc Stock (ANAB) Latest News

Sep 24, 2026

ANAB Reiterated by HC Wainwright & Co. -- Price Target Maintained at $95 - GuruFocus

Sep 24, 2026

Q3 Earnings Estimate for AnaptysBio Issued By HC Wainwright - MarketBeat

Sep 24, 2026

Sep 23, 2026

ANAB Maintained by Leerink Partners -- Price Target Lowered to $81 - GuruFocus

Sep 23, 2026

Leerink Partners Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat

Sep 23, 2026

Leerink Partners maintains Outperform rating on AnaptysBio, $81 price target - TradingView

Sep 23, 2026

AnaptysBio (ANAB) Flags Positive AZUR 1 Data With Approval And Legal Timelines - simplywall.st

Sep 23, 2026

Bank of America Corp DE Makes New $28.20 Million Investment in AnaptysBio, Inc. $ANAB - MarketBeat

Sep 23, 2026

AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Sep 23, 2026

Sep 22, 2026

AnaptysBio earnings analysis: questions answered and next catalysts - Investing.com

Sep 22, 2026

AnaptysBio (NASDAQ:ANAB) Shares Down 6.2%What's Next? - MarketBeat

Sep 22, 2026